
Ash 2022 preview – waiting for Editas
Data on the group’s sickle cell project do not feature in the regular abstracts, while Bluebird walks away from its short hairpin contender.

Ash 2021 – Sangamo and Sanofi enter the sickle cell gene editing fray
SAR445136 could take on Crispr and Vertex’s CTX001, but plenty of other groups have the same idea.

Biotech listings shows few signs of cooling
IPOs of drug developers raised $9bn in the first half of 2021, a record amount that is hard to square with talk of moderation.